Liquid Fungal Cocultivation as a Strategy to Access Bioactive Metabolites

Abstract

Fungi are a rich source of bioactive compounds. Fungal cocultivation is a method of potentiating chemical interactions and, consequently, increasing bioactive molecule production. In this study, we evaluated the bactericidal, antiprotozoal, and cathepsin V inhibition activities of extracts from axenic cultures of 6 fungi (Fusarium guttiforme, Pestalotiopsis diospyri, Phoma caricae-papayae, Colletotrichum horii, Phytophthora palmivora, and C. gloeosporioides) that infest tropical fruits and 57 extracts obtained by their cocultivation. Our results reveal that fungal cocultivation enhances the biological activity of the samples, since all extracts that were active on Gram-positive bacteria, Gram-negative bacteria, Trypanosoma cruzi, and Leishmania infantum were obtained from cocultivation. Bacterial growth is either totally or partially inhibited by 46% of the extracts. Two extracts containing mainly fusaric and 9,10-dehydrofusaric acids were particularly active. The presence of the fungus F. guttiforme in co-cultures that give rise to extracts with the highest activities against L. infantum. An axenic culture gave rise to the most active extract for the inhibition of cathepsin V; however, other coculture extracts also exhibited activity toward this biological target. Therefore, the results of the biological activities indicate that fungal cocultivation increased the biological potential of samples, likely due to the hostile and competitive environment that pushes microorganisms to produce substances important for defense and allows access to metabolic routes then silenced in milder cultivation conditions.

Key words

antibacterial activity - antiprotozoal activity - cathepsin V inhibition - Fusarium - Pestalotiopsis - Phoma - Phytophthora - Colletotrichum

Publication History

Received: 27 March 2020

Accepted after revision: 05 June 2020

Article published online:
09 July 2020

• References

• 1 Newman DJ, Cragg GM. Natural products as sources of new drugs from 1981 to 2014. J Nat Prod 2016; 79: 629-661
• 2 Martinez-Klimova E, Rodriguez-Peña K, Sänchez S. Endophytes as sources of antibiotics. Biochem Pharmacol 2017; 134: 1-17
• 3 Cragg GM, Newman DJ. Natural products: a continuing source of novel drug leads. Biochim Biophys Acta Gen Subj 2013; 1830: 3670-3695
• 4 Savi DC, Aluizio R, Glienke C. Brazilian plants: an unexplored source of endophytes as producers of active metabolites. Planta Med 2019; 85: 619-636
• 5 Bertrand S, Bohni N, Schnee S, Schumpp O, Gindro K, Wolfender JL. Metabolite induction via microorganism co-culture: a potential way to enhance chemical diversity for drug discovery. Biotechnol Adv 2014; 32: 1180-1204
• 6 Caraballo-Rodríguez AM, Dorrestein PC, Pupo MT. Molecular inter-kingdom interactions of endophytes isolated from Lychnophora ericoides . Sci Rep 2017; 7: 5373
• 7 Chagas FO, Pupo MT. Chemical interaction of endophytic fungi and actinobacteria from Lychnophora ericoides in co-culture. Microbiol Res 2018; 213: 10-16
• 8 Marmann A, Aly AH, Lin W, Wang B, Proksch P. Co-cultivation – a powerful emerging tool for enhancing the chemical diversity of microorganisms. Mar Drugs 2014; 12: 1043-1065
• 9 Vigneshwari R, Roopavathi AS, Jayapradha R. Cocultivation – powerful tool for the production of secondary metabolites. J Chem Pharm Res 2015; 7: 481-485
• 10 Moody S. Microbial co-culture: harnessing intermicrobial signaling for the production of novel antimicrobials. Future Microbiol 2014; 9: 575-578
• 11 Damasceno Silva A, Ambrozin ARP, Carneiro RL, Vieira PC. A new approach for identifying antagonism among fungi species and antifungal activity. J Pharm Biomed Anal 2020; 179: 112960
• 12 Wu C, Zacchetti B, Ram AFJ, van Wezel GP, Claessen D, Choi YH. Expanding the chemical space for natural products by Aspergillus-Streptomyces co-cultivation and biotransformation. Sci Rep 2015; 5: 10868
• 13 Rateb ME, Hallyburton I, Houssen WE, Bull AT, Goodfellow M, Santhanam R, Jaspars M, Ebel R. Induction of diverse secondary metabolites in Aspergillus fumigatus by microbial co-culture. RSC Adv 2013; 3: 14444
• 14 Zhu F, Chen G, Chen X, Huang M, Wan X. Aspergicin, a new antibacterial alkaloid produced by mixed fermentation of two marine-derived mangrove epiphytic fungi. Chem Nat Compd 2011; 47: 767-769
• 15 Bacon CW, Porter JK, Norred WP, Leslie JF. Production of fusaric acid by Fusarium species. Appl Environ Microbiol 1996; 62: 4039-4043
• 16 Tung TT, Jakobsen TH, Dao TT, Fuglsang AT, Givskov M, Christensen SB, Nielsen J. Fusaric acid and analogues as Gram-negative bacterial quorum sensing inhibitors. Eur J Med Chem 2017; 126: 1011-1020
• 17 Sondergaard TE, Fredborg M, Christensen AMO, Damsgaard SK, Kramer NF, Giese H, Sorensen JL. Fast screening of antibacterial compounds from Fusaria. Toxins (Basel) 2016; 8: 354-362
• 18 May HD, Wu Q, Blake CK. Effects of the Fusarium spp. mycotoxins fusaric acid and deoxynivalenol on the growth of Ruminococcus albus and Methanobrevibacter ruminantium . Can J Microbiol 2000; 46: 692-699
• 19 Son SW, Kim HY, Choi GJ, Lim HK, Jang KS, Lee SO, Lee S, Sung ND, Kim JC. Bikaverin and fusaric acid from Fusarium oxysporum show antioomycete activity against Phytophthora infestants . J Appl Microbiol 2008; 104: 692-698
• 20 Bacon CW, Hinton DM, Hinton jr. A. Growth-inhibiting effects of concentrations of fusaric acid on the growth of Bacillus mojavensis and other biocontrol Bacillus species. J Appl Microbiol 2006; 100: 185-194
• 21 Capasso R, Evidente A, Cutignano A, Vurro M, Zonno MC. Fusaric and 9,10-dehydrofusaric acids and their methyl esters from Fusarium nygamai . Phytochemistry 1996; 41: 1035-1039
• 22 Idris AE, Abouzeid MA, Boari A, Vurro M, Evidente A. Identification of phytotoxic metabolites of a new Fusarium sp. inhibiting germination of Striga hermonthica seeds. Phytopathol Mediterr 2003; 42: 65-70
• 23 Drenkard E. Antimicrobial resistance of Pseudomonas aeruginosa biofilms. Microbes Infect 2003; 5: 1213-1219
• 24 Rosa LH, Gonçalves VN, Caligiorne RB, Alves TMA, Rabello A, Sales PA, Romanha AJ, Sobral MEG, Rosa CA, Zani CL. Leishmanicidal, trypanocidal, and cytotoxic activities of endophytic fungi associated with bioactive plants in Brazil. Braz J Microbiol 2010; 41: 420-430
• 25 Guimarães DO, Borges WS, Kawano CY, Ribeiro PH, Goldman GH, Nomizo A, Thiemann OH, Oliva G, Lopes NP, Pupo MT. Biological activities from extracts of endophytic fungi isolated from Viguiera arenaria and Tithonia diversifolia . FEMS Immunol Med Microbiol 2008; 52: 134-144
• 26 Turk B. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 2006; 5: 785-799
• 27 Dong Y, Lin J, Lu X, Zheng Z, Ren X, Zhang H, He J, Yang J. Cathepsin B inhibitory tetraene lactones from the fungus Talaromyces wortmannii . Helv Chim Acta 2009; 92: 567-574
• 28 Isshiki K, Asai Y, Tanaka S, Nishio M, Uchida T, Okuda T, Komatsubara S, Sakurai N. Aurantiameid acetate, a selective cathepsin inhibitor, produced by Aspergillus penicilloides . Biosci Biotechnol Biochem 2001; 65: 1195-1197
• 29 Yu CM, Curtis JM, Walter JA, Wright JLC, Ayer SW, Kaleta J, Querengesser L, Fathi-Afshar ZR. Potent inhibitors of cysteine proteases from the marine fungus Microascus longirostris . J Antibiot 1995; 49: 395-397
• 30 Sabotic J, Kos J. Microbial and fungal protease inhibitors – current and potential applications. Appl Microbiol Biotechnol 2012; 93: 1351-1375
• 31 Brzin J, Rogelj B, Popovic T, Strukelj B, Ritonja A. Clitocypin, a new type of cysteine proteinase inhibitor form fruit bodies of mushroom Clitocybe nebularis . J Biol Chem 2000; 275: 20104-20109
• 32 Severino RP, Guido RVC, Marques EF, Brömme D, da Silva MFGF, Fernandes JB, Andricopulo AD, Vieira PC. Acridone alkaloids as potent inhibitors of cathepsin V. Bioorg Med Chem 2011; 19: 1477-1481
• 33 Sarria ALF, Silva TL, de Oliveira JM, de Oliveira MAR, Fernandes JB, da Silva MFGF, Vieira PC, Venancio T, Alves Filho EG, Batista jr. JM, Guido RVC. Dimeric chalcones derivatives from Myracrodruon urundeuva act as cathepsin V inhibitors. Phytochemistry 2018; 154: 31-38
• 34 Silva TL, Fernandes JB, da Silva MFGF, Consolaro HN, de Sousa LRF, Vieira PC. New cathepsin V inhibitor from stems of Bowdichia virgilioides . Rev Bras Farmacogn 2019; 29: 491-494
• 35 CLSI. Performance Standards for antimicrobial Susceptibility Testing. 27th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2017
• 36 CLSI. Methods for Dilution antimicrobial Susceptibility Tests for Bacteria that grow aerobically. Approved standard, 10th Edition. CLSI document M07-A10. Wayne, PA: Clinical and Laboratory Standards Institute; 2015
• 37 Gupta S. Visceral leishmaniasis: experimental models for drug discovery. Indian J Med Res 2011; 133: 27-39
• 38 Ioset JR, Brun R, Wenzler T, Kaiser M, Yardley V. Drug Screening for Kinetoplastid Diseases. A Training Manual for Screening in Neglected Diseases. Geneva: DNDi and Pan-Asian Screening Network; 2009
• 39 Shimony O, Jaffe CL. Rapid fluorescent assay for screening drugs on Leishmania amastigotes. J Microbiol Methods 2008; 75: 196-200
• 40 Mikus J, Steverding D. A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue. Parasitol Int 2000; 48: 265-269
• 41 Ferreira RAA, Pauli I, Sampaio TS, de Souza ML, Ferreira LLG, Magalhães LG, Rezende jr. CO, Ferreira RS, Krogh R, Dias LC, Andricopulo AD. Structure-based and molecular modeling studies for the discovery of cyclic imides as reversible cruzain inhibitors with ootent anti-Trypanosoma cruzi activity. Front Chem 2019; 7: 798
• 42 Bromme D, Li Z, Barnes M, Mehler E. Human cathepsin V functional expression, tissue distribution, electrostatic surface, enzymatic characterization and chromosomal localization. Biochem 1999; 38: 2377-2385
• 43 Barret AJ, Kembhavi AA, Brown MA, Kirschke H, Knight CG, Tamait M, Hanadat K. L-trans-epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem J 1982; 201: 189-198